Subject: RE: Retroactive financing of covid-19 vaccine expenditures
From: Volkan Cetinkaya <[email-masked]>
To: Nino Kvernadze <[email-masked]>
Cc: Ekaterine Tikaradze <[email-masked]>, "[email-masked]" <[email-masked]>, Tamar Tsenteradze <[email-masked]>, Nino Ramishvili <[email-masked]>, Jelena Lukic <[email-masked]>, Damir Leljak <[email-masked]>, Maddalena Honorati <[email-masked]>, Natalie Godziashvili <[email-masked]>, Lia Tavadze <[email-masked]>, "[email-masked]" <[email-masked]>, "Nino V. Moroshkina" <[email-masked]>, Beka Jakeli <[email-masked]>, Maia Nikoleishvili <[email-masked]>, Natia Khmaladze <natkhmaladze
Date: Thu, 18 Feb 2021 01:19:47 +0000

Hi Nino,

Thanks for the information on retroactive financing needs. During the project preparation, if the need is definitely higher than 20%, we could prepare a memo to request the Vice President’s approval. I don’t think it would be a problem.
Our request for higher RF in another country is recently approved.

Best,

Volkan

From: Nino Kvernadze

Sent: Tuesday, February 16, 2021 10:52 AM

To: Volkan Cetinkaya

Cc: Ekaterine Tikaradze ; [email-masked]; Tamar Tsenteradze ; Nino Ramishvili ; Jelena Lukic ; Damir Leljak ; Maddalena Honorati
; Natalie Godziashvili ; Lia Tavadze ; [email-masked]; Nino V. Moroshkina ; Beka Jakeli ; Maia Nikoleishvili ;
Natia Khmaladze

Subject: RE: Retroactive financing of covid-19 vaccine expenditures

[External]

Dear Volkan,

Thank you very much for your reply. Since the Project restructuring takes time, retroactive financing of eligible vaccines expenditures is a very important instrument.  We hope that the share of retroactive financing will be around 30-40%
of the loan amount.

Regarding the NCDC, this is a Legal Entity of Public Law under the Ministry of Health. Hence according to your questions, there should not be any problem on the reimbursement side.  However, the issue is now solved, since ongoing procurements
will be made by the Ministry itself.

Thank you for your cooperation!

Kind regards,

Nino Kvernadze

From: Volkan Cetinkaya <[email-masked]>

Sent: 8 February, 2021 23:24

To: Nino Kvernadze <[email-masked]>

Cc: Ekaterine Tikaradze <[email-masked]>; Tamar Gabunia <[email-masked]>; Tamar Tsenteradze <[email-masked]>;
Nino Ramishvili <[email-masked]>; Jelena Lukic <[email-masked]>; Damir Leljak <[email-masked]>; Maddalena
Honorati <[email-masked]>; Natalie Godziashvili <[email-masked]>; Lia Tavadze <[email-masked]>; Nino
Gvenetadze <[email-masked]>; Nino V. Moroshkina <[email-masked]>; Beka Jakeli <[email-masked]>; Maia Nikoleishvili
<[email-masked]>

Subject: RE: No-objection request

Dear Nino,

The Covid-19 vaccines will be eligible for retroactive financing
if the purchase meets all WB conditions for vaccine financing/deployment. Additionally on the vaccine approval – this means that they be eligible for Bank financing if at the time of disbursement, the vaccines meet the Bank’s vaccine eligibility criteria.
For e.g., some vaccines are currently not eligible for Bank financing (Russian and Chinese vaccines, or vaccines with lack of WHO/other regulatory authorization).

As long as these vaccines meet the eligibility criteria, the World Bank loan would cover NCDC’s vaccine expenditures retroactively. However, going forward, we need to address some questions about NCDC from a legal and operational perspective
such as what is the nature of this agency? is it legally and financially independent from MoH? is it entering into contracts with the pharmaceutical corporations under its own name or on behalf of MoH? Based on the answers for these questions, relevant documents
including the Loan Agreement will be revised.

Best,

Volkan

From: Nino Kvernadze <[email-masked]>

Sent: Thursday, February 04, 2021 3:24 AM

To: Volkan Cetinkaya <[email-masked]>

Cc: Ekaterine Tikaradze <[email-masked]>;
[email-masked]; Tamar Tsenteradze <[email-masked]>; Nino Ramishvili <[email-masked]>; Jelena
Lukic <[email-masked]>; Damir Leljak <[email-masked]>; Maddalena Honorati <[email-masked]>; Natalie Godziashvili
<[email-masked]>; Lia Tavadze <[email-masked]>;
[email-masked]; Nino V. Moroshkina <[email-masked]>; Beka Jakeli <[email-masked]>; Maia Nikoleishvili <[email-masked]>

Subject: RE: No-objection request

[External]

Dear Volkan,

Thank you for your email.

In this case our understanding is that after restructuring, retroactive financing of vaccine procurement, along with the related costs incurred by the Ministry or its subordinated - NCDC will be approved from
the WB’s side.

Could you please confirm that our understanding is correct?

Kind regards,

Nino Kvernadze

From: Volkan Cetinkaya <[email-masked]>

Sent: 3 February, 2021 19:13

To: Nino Kvernadze <[email-masked]>

Cc: Ekaterine Tikaradze <[email-masked]>; Tamar Gabunia <[email-masked]>; Tamar Tsenteradze <[email-masked]>;
Nino Ramishvili <[email-masked]>; Jelena Lukic <[email-masked]>; Damir Leljak <[email-masked]>; Maddalena
Honorati <[email-masked]>; Natalie Godziashvili <[email-masked]>; Lia Tavadze <[email-masked]>; Nino
Gvenetadze <[email-masked]>; Nino V. Moroshkina <[email-masked]>; Beka Jakeli <[email-masked]>; Maia Nikoleishvili
<[email-masked]>

Subject: RE: No-objection request

Dear Nino,

This will require restructuring the COVID-19 project. We are under strict instructions that any vaccine procurement financing needs to go to the Operations Committee review and Board approval.

The World Bank senior management, including the Vice President and Country Director, will meet with the Prime Minister on Friday. I believe that one of the discussion point is World Bank’s potential support, such as additional financing,
for the COVID-19 vaccine. I would suggest to discuss your request below and next steps based on the outcome of this meeting.

Best,

Volkan

From: Nino Kvernadze <[email-masked]>

Sent: Monday, February 01, 2021 11:14 AM

To: Volkan Cetinkaya <[email-masked]>

Cc: Ekaterine Tikaradze <[email-masked]>;
[email-masked]; Tamar Tsenteradze <[email-masked]>; Nino Ramishvili <[email-masked]>; Jelena
Lukic <[email-masked]>; Damir Leljak <[email-masked]>; Maddalena Honorati <[email-masked]>; Natalie Godziashvili
<[email-masked]>; Lia Tavadze <[email-masked]>;
[email-masked]; Nino V. Moroshkina <[email-masked]>; Beka Jakeli <[email-masked]>; Maia Nikoleishvili <[email-masked]>

Subject: RE: No-objection request

[External]

Dear Volkan,

Dear Team,

As communicated earlier, within the frame of the commitments brokered recently, Georgia is eligible for receiving at least 29,250 doses of the Pfizer-BioNTech COVID-19 Vaccine (https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/standing-orders.pdf
) through the COVAX Platform, as early as mid-February 2021.

Furthermore, GAVI and WHO partners are committed to proceeding with allocating 184,800 - 314,400 doses of AstraZeneca/Oxford vaccine to Georgia, starting from 1st quarter of the 2021 year; -
minimum 46200-64680 but maximum 78600-110040 doses will be available at the time, to cover the 25-35% of the needed vaccines if realized.  That leaves the rest 65-75% of needed doses to be received in 2nd quarter of the current year of 2021.

Having that outlined above, at this stage, this is paramount to ensure mobilization of the necessary financial resource, tentatively 350 000 USD, to cover the cost of 1st tranche of  29,250 doses
of the Pfizer-BioNTech COVID-19 Vaccine to arrive in mid-February.

The fastest solution toward securing the financial means would be relying on the Bank’s support to give its No Objection for accommodating the amount (350 000 USD) under the IBRD/AIIB Loan Agreement
with GoG for COVID-19 Emergency Response Project. The allocated budget line for such procurements would be Procurement of Diagnostic Supplies, with - at this stage  available funds of 4.3 ml. approximately.

We hereby request your kind agreement on the above, and the PIU remains ready to facilitate the transaction further, in compliance with the World Bank’s procedures defined for this procurement,
and the related Government documents available in the official document system already.

In addition, we are sharing with you English version of Georgia COVID-19 Vaccine National Deployment Plan, approved by the Governmental Resolution #67 as of
January 21, 2021  January 18.

Best regards,

Nino Kvernadze

From: Tamar Gabunia <[email-masked]>

Sent: 15 January, 2021 20:47

To: Volkan Cetinkaya <[email-masked]>; Nino Kvernadze <[email-masked]>

Cc: Tamar Tsenteradze <[email-masked]>; Nino Ramishvili <[email-masked]>; Jelena Lukic <[email-masked]>;
Damir Leljak <[email-masked]>; Maddalena Honorati <[email-masked]>; Natalie Godziashvili <[email-masked]>;
Lia Tavadze <[email-masked]>; Nino Gvenetadze <[email-masked]>; Nino V. Moroshkina <[email-masked]>

Subject: RE: No-objection request for direct procurement of 50 000 pcs of 0.3 ml AD syringes for vaccination

Dear Volkan

Many thanks for your e-mail and willingness to consider granting no objection on procuring 50 000 AD syringes for the a Pfizer-BioNTech COVID-19 Vaccine program. Hereby I would like to confirm that

(1) the Ministry is currently working with the COVAX platform to secure a Pfizer-BioNTech COVID-19 Vaccine in Q1 of 2021, the national COVID vaccination program will be using more than 1 vaccine and we will switch
to another vaccine which may become available through COVAX platform at a late stage.

(2) NCDC/Lugar’s Center has adequate cold chain capacity to store the Pfizer-BioNTech COVID-19 Vaccine in accordance with the requested conditions. VIF recently submitted to the COVAX platform is attached for
additional details.

(3) As for the regulatory authorization, in line with the Law of Georgia on “Medicines and Pharmaceutical Activities” (Article 1113) and corresponding Order N327/n of the Minister of Labour, Health and Social
Affairs of Georgia of October 13, 2009 the Ministry shall grant the import authorization for the Pfizer vaccine in January 2021 (once available). The import authorization for the Pfizer vaccine will rely on WHO Emergency Use Listing or Emergency Use Authorization
or equivalent by a WHO designated Stringent Regulatory Authority (SRA). The product can be important with standard labels without additional inserts nor translation in a language other than UN languages (Spanish, French, Arabic, English, Chinese and Russian)
be required.

In order to meet the necessary indemnity and liability requirements, the Parliament of Georgia has already initiated the legislative amendments to the law of Georgia on “Public Health”. The amendment clearly
defines the role and responsibilities of the State in terms of indemnity and liability associated with the use and deployment of Covid-19 vaccines. The legislation procedures will be finalized in expedited manner (the first Committee hearing took place on
January 12th) and amendment will come into force by the end of January, 2021. Based on this amendment, the Ministry will be able to complete an agreement with Pfizer immediately to indemnify the manufacturer for product liability claims associated with the
use or administration of that vaccine.

Should you have additional questions please kindly let me know.

პატივისცემით,

თამარ გაბუნია

მინისტრის პირველი მოადგილე

Sincerely,

Tamar Gabunia,
MD, MPH

First Deputy Minister

From: Volkan Cetinkaya [mailto:[email-masked]]

Sent: 15 January, 2021 18:17

To: Nino Kvernadze <[email-masked]>

Cc: Tamar Gabunia <[email-masked]>; Tamar Tsenteradze <[email-masked]>; Nino Ramishvili <[email-masked]>;
Jelena Lukic <[email-masked]>; Damir Leljak <[email-masked]>; Maddalena Honorati <[email-masked]>; Natalie
Godziashvili <[email-masked]>; Lia Tavadze <[email-masked]>; Nino Gvenetadze <[email-masked]>; Nino V.
Moroshkina <[email-masked]>

Subject: RE: No-objection request for direct procurement of 50 000 pcs of 0.3 ml AD syringes for vaccination

Dear Nino,

Thank you very much for your email and all relevant correspondence sent on January 14, 2021. Based on the information provided, the Bank has no objection to procure 50,000 AD syringes from the Indian company Hindustan Syringes & Medical
Devices Ltd. on the condition that the Government of Georgia:

plans to purchase a Pfizer-BioNTech COVID-19 Vaccine;

is prepared to store the Pfizer-BioNTech COVID-19 Vaccine in accordance with the requested conditions;

planning to procure a certified Pfizer-BioNTech COVID-19 Vaccine;

The Bank recommends that all subsequent documents (including this correspondence) be uploaded to STEP and made available for later post review to be conducted.

Please send a copy of the signed contract to the Bank before requesting or making any payments under this contract.

Sincerely,

Volkan

From: Nino Kvernadze <[email-masked]>

Sent: Wednesday, January 13, 2021 2:39 PM

To: Volkan Cetinkaya <[email-masked]>

Cc: [email-masked]; Tamar Tsenteradze <[email-masked]>; Nino Ramishvili <[email-masked]>;
Jelena Lukic <[email-masked]>; Damir Leljak <[email-masked]>; Maddalena Honorati <[email-masked]>; Natalie
Godziashvili <[email-masked]>; Lia Tavadze <[email-masked]>;
[email-masked]; Nino V. Moroshkina <[email-masked]>

Subject: No-objection request for direct procurement of 50 000 pcs of 0.3 ml AD syringes for vaccination

[External]

Dear Volkan,

Dear Team,

Following our communication previously, on COVAX facility, which the GoG has prioritized as a main platform to support Georgia’s commitment to provide COVID-19 Vaccination to priority populations, we would like to return to this important
matter with some overview of the background, and current dynamics and evolving needs to directly procure AD syringes,  considered to be supported under the PIU further.

At a current stage, as Pfizer-BioNTech COVID-19 Vaccine (https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/standing-orders.pdf
) obtained wide recognition through WHO and US FDA / CDC listings, and following GAVI Alliance Director’s special message (https://www.gavi.org/vaccineswork/gavi-covax-amc-explained
) explaining opportunities for AMC (Advance Market Commitment) countries, Georgia could be part of “first wave’ distribution for limited number of target populations.

Namely, based on assessment regarding adequate preparedness for the vaccine deployment, the country would be eligible to receive the vaccine for front line health personnel (within established 0,25% of the total population per AMC country).

Within the frame above, and according to recommendations for the vaccine administration, the Ministry is intending to urgently procure the 0,3ml volume AD syringes, directly from one of WHO prequalified manufacturers - Hindustan Syringes
& Medical Devices Ltd. – relevant email communication enclosed.

Notably,  the NCDC&PH point person has also been in contact with another WHO prequalified manufacturer of needed syringes in China, but they work mostly with bigger packages of orders and no agreement has been possible to achieve at this
stage. Only mentioned two companies have WHO’s prequalifications so far (
Hindustan Syringes & Medical Devices Ltd.and
Wuxi Yushou Medical Appliances Co., Ltd)

WHO link:   https://apps.who.int/immunization_standards/vaccine_quality/pqs_catalogue/categorypage.aspx?id_cat=37

Neither UNICEF country office will be able to broker the needed deal via the Agency’s relevant global mechanism, due to the long waiting list of standing orders already placed from other countries.

With this email, the Ministry through the PIU, requests the WB, to consider this urgent procurement of 50 000 pcs of 0,3ml AD syringes needed to be stocked in advance to guarantee preparedness for administering the Pfizer-BioNTech COVID-19
Vaccine to front-line health personnel playing paramount role in the COVID-19 emergency response in Georgia. The total price would be approximately 4000 US (please find  invoice attached).  The budget line for this activity would be diagnostic and supplies
of the PP.

We hereby request WB’s no-objection to proceed with direct procurement of 50 000 pcs AD syringes, from the Indian company
Hindustan Syringes & Medical Devices Ltd.

For more clarity, please find below some basic background information on COVAX platform and Georgia’s membership below:

On 24 April 2020, the World Health Organization (WHO) hosted the launch of the Access to COVID-19 Tools (ACT) Accelerator, a new global collaboration to accelerate development, production, and equitable access
to COVID-19 diagnostics, therapeutics, and vaccines (https://www.who.int/initiatives/act-accelerator
). - The COVAX (https://www.who.int/initiatives/act-accelerator/covax#:~:text=COVAX%20is%20co%2Dled%20by,every%20country%20in%20the%20world
), the act-accelerator vaccines pillar, is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO. Its COVAX Facility (https://www.gavi.org/covid19/covax-facility
) aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.

Through supporting financially the world’s prominent manufacturers’ active portfolios of front-runner candidate vaccines, the COVAX Facility ensures participant countries’ equal access to essential doses of vaccine(s);

On 31st August the MoILHSA of Georgia signed the standard affiliation / commitment letter with the COVAX Facility, which is also providing for selecting purchase model from the 2 available mechanisms under the
Facility. – Optional Purchase model has been selected for its flexibilities applied. Under the same commitment, at least 20% of the country’s population will be covered, and with 2-dose series of vaccination 1,484,400 doses (“total participant doses”) of the
vaccine will be a target to allocate.

On 18 September 2020 duly signed Agreement between GAVI and the Ministry on behalf of the GoG was presented to the Facility, and following the signing of the Agreement, the committed “Upfront Payment” to the
Facility: ($3.10 per dose) US$4,601,640 was covered from the Georgia State Budget, plus the “Risk Sharing Guarantee Amount” US$593,760 also paid in advance.

(Full cost of “Total Participant Doses” meaning 1,484,400 number of doses of “Approved Vaccine”, sufficient to vaccinate 20% of the Participant’s Population, ($10.55 per single dose) makes $15,660,420 total.

The COVAX Facility also leaves it at the country’s full discretion to define the financial sources to participate in the Facility, whether it is state budget, contributions from international financial institutions, or other investment instruments.)

We hereby ask your immediate attention to this matter, since the notice period for the Ministry to COVAX, whether Georgia is able to get AD syringes, is January 18.

Kind regards,

ნინო კვერნაძე

პროექტის მენეჯერი,

მსოფლიო ბანკის COVID-19-ის წინააღმდეგ სწრაფი რეაგირების

პროექტის განმახორციელებელი ჯგუფი
(PIU),

საქართველოს ოკუპირებული ტერიტორიებიდან დევნილთა, შრომის, ჯანმრთელობისა და სოციალური
დაცვის სამინისტრო

www.moh.gov.ge

Nino Kvernadze

Project Manager, PIU – World Bank

Emergency COVID-19 Response Project Implementation Unit

Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia

www.moh.gov.ge

Email:
[email-masked]

Cell: +995 599 18 46 44;
office: +995322510011/0506

From: Nino Kvernadze <[email-masked]>

Sent: 18 September, 2020 19:55

To: Volkan Cetinkaya <[email-masked]>

Cc: Tamar Gabunia <[email-masked]>;
[email-masked]; Salome Chakvetadze <[email-masked]>; Tanvir Hossain <[email-masked]>; Nino Ramishvili <[email-masked]>;
Tamar Tsenteradze <[email-masked]>; Maddalena Honorati <[email-masked]>; Nino V. Moroshkina <[email-masked]>;
Nino Gvenetadze <[email-masked]>; Lia Tavadze <[email-masked]>; Ketevan Goginashvili <[email-masked]>;
Beka Jakeli <[email-masked]>

Subject: Information on COVAX - facility

Dear Volkan,

With this email PIU team is sharing with you the basic information on COVAX facility, which we think will be very helpful to proceed further. Please
find information below:

On 24 April 2020, the World Health Organization (WHO) hosted the launch of the Access to COVID-19 Tools (ACT) Accelerator, a new global collaboration
to accelerate development, production, and equitable access to COVID-19 diagnostics, therapeutics, and vaccines (https://www.who.int/initiatives/act-accelerator
).

COVAX (https://www.who.int/initiatives/act-accelerator/covax#:~:text=COVAX%20is%20co%2Dled%20by,every%20country%20in%20the%20world
), the act-accelerator vaccines pillar, is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO.

Its COVAX Facility (https://www.gavi.org/covid19/covax-facility
) aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.

Through supporting financially the world’s prominent manufacturers’ active portfolios of front-runner candidate vaccines, the COVAX Facility ensures
participant countries’ equal access to essential doses of vaccine(s); - this is expected that by end of 2021, 2 bln. doses of new developed vaccine(s) will be available to purchase for all participants of the Facility.  - Importantly, it’s calculated that
$11.3 B is needed urgently to cover needed investments within the next 6 months. This includes almost $2 B in immediate funding for advance market commitments to secure doses for LMICs.

At a current stage, unprecedented race for development of COVID-19 vaccine is still under way, with over 300 proposals and only 9 candidate vaccines
among them actively supported by the facility. From these, 7 are at the stage of clinical trials.

On 31st August the MoILHSA of Georgia signed the standard affiliation / commitment letter with the COVAX Facility, which is also providing
for selecting purchase model from the 2 available mechanisms under the Facility. – Optional Purchase model has been selected for its flexibilities applied. Under the same commitment, probable coverage rate of the vaccination has been defined: at least 20%
of the country’s population will be covered, and if 2-dose series of vaccination adopted then 1,484,400 doses (“total participant doses”) of the vaccine will be essential to allocate.

By participating in the COVAX Facility, the Participant will have access to doses of vaccine candidates as a result of the advance purchase commitments
that Gavi will conclude with vaccine manufacturers. As doses from successful candidates become available, a Participant will be given the opportunity to purchase Approved Vaccines from manufacturers. (excerpt from guiding documents)

Importantly, the Optional Purchase model also provides for possibility of rejecting a vaccine offered, as the country will have a discretion on choosing
among possible available options (“purchase opportunities”), the same time, securing full amount of assigned doses, but accepting certain delays if concrete opportunity was rejected. - This is paramount, as the participant countries stay conscious of the realistic
expectation that only 1 or 2 vaccines can be available at initial stages, in a limited amount of doses.

In case of rejecting concrete “purchase opportunity”, the participant country receives prepaid doses of acceptable vaccine. Also importantly, if all
assigned doses are not purchased under the facility, the “risk sharing guarantee” payment is retained, as irrevocable.  – For all terms and definitions, see please the annexed Commitment Agreement / Optional Purchase Arrangement, received from GAVI on 8th
September 2020 via email communication, compliant with the terms and conditions outlined in the letter confirming engagement of Georgia with the Facility, signed by the Ministry on 31st August 2020.

18 September 2020 is a deadline of presenting a duly signed Agreement between GAVI and the Ministry on behalf of the GoG to the Facility.

After the signing the Agreement, 9 October is a deadline to cover the committed advance payments to the Facility, outlined in the Agreement:

“Upfront Payment” ($3.10 per dose) which means US$4,601,640,

(Full cost of “Total Participant Doses” meaning 1,484,400 number of doses of “Approved Vaccine”, sufficient to vaccinate 20% of the Participant’s Population,
($10.55 per single dose) makes $15,660,420 total.)

The “Risk Sharing Guarantee Amount”, which means US$593,760, must be also paid in advance.

The COVAX Facility also leaves it at the country’s full discretion to define the financial sources to participate in the Facility, whether it is state
budget, contributions from international financial institutions, or other investment instruments.

Therefore, the MoILHSA intends to mobilize the funds from the Georgia Emergency COVID-19 Emergency Project, supported by the World Bank Group, to accommodate
the upfront and guarantee payments to the Facility, - $5,195,400 totally.

Through the PIU, the First Deputy Minister of MoILHSA conveys the Ministry’s great appreciation to the World Bank Group, for considering inclusion of
such payment of paramount importance to the COVID-19 emergency response within the priority procurement plan of the Project.

Kind regards,

ნინო კვერნაძე

პროექტის მენეჯერი,

მსოფლიო ბანკის COVID-19-ის წინააღმდეგ სწრაფი რეაგირების

პროექტის განმახორციელებელი ჯგუფი (PIU),

საქართველოს ოკუპირებული ტერიტორიებიდან დევნილთა, შრომის, ჯანმრთელობისა და სოციალური დაცვის სამინისტრო

www.moh.gov.ge

Nino Kvernadze

Project Manager, PIU – World Bank

Emergency COVID-19 Response Project Implementation Unit

Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia

www.moh.gov.ge

Email:
[email-masked]

Cell: +995 599 18 46 44